Back to Journals » OncoTargets and Therapy » Volume 8
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,854 | Dovepress* | 7,883+ | 1,814 | 9,697 | |
PubMed Central* | 971 | 463 | 1,434 | ||
Totals | 8,854 | 2,277 | 11,131 | ||
*Since 14 May 2015 +Since July 2016 |
View citations on PubMed and Google Scholar